Patent: 8,383,359
✉ Email this page to a colleague
Summary for Patent: 8,383,359
| Title: | Use of lymphocytes to measure anthrax lethal toxin activity |
| Abstract: | It is disclosed herein that isolated lymphocytes, such as human B-cells and CD4.sup.+ T-cell can be used to determine an amount of lymphocyte-associated anthrax lethal toxin activity present. Methods of using isolated lymphocytes to identify anthrax therapeutic agents and to determine the efficacy of a potential anthrax therapeutic are disclosed. Methods are also provided for diagnosing and treating anthrax infections. |
| Inventor(s): | Frucht; David M. (Vienna, VA), Fang; Hui (Germantown, MD) |
| Assignee: | The United States of America as represented by the Secretary of the Department of Health and Human Services (Washington, DC) N/A (N/A) |
| Application Number: | 12/889,955 |
| Patent Claims: | see list of patent claims |
Details for Patent 8,383,359
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Emergent Biodefense Operations Lansing Llc | BIOTHRAX | anthrax vaccine adsorbed | Injection | 103821 | 11/12/1998 | ⤷ Try a Trial | 2025-04-05 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
